Sanjay Subramanian
CIK 1790246 · SVP, CFO & Head of BD · last filed 2025-07-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$195.0K
Companies
2
Total Filings
26
Lifetime Open-Market Net
-$1.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Inozyme Pharma, Inc. (INZY) Delisted | SVP, CFO & Head of BD | 39,701 | $4.00 | $158.8K | $100.0K | 9 | 2025-06-27 |
| OCGN | Chief Financial Officer | 161,125 | $1.21 | $195.0K | -$1.16M | 16 | 2022-01-05 |
Recent Filings · Page 2 of 3
26 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-05 | OCGN | Grant (A) | +125,534 | $0 | EDGAR |
| 2021-12-17 | OCGN | Grant (A) | — | $0 | EDGAR |
| 2021-11-18 | OCGN | Grant (A) | — | $0 | EDGAR |
| 2021-10-27 | OCGN | Sell (S) | −10,000 | -$110.7K | EDGAR |
| 2021-10-15 | OCGN | Mixed | — | -$62.1K | EDGAR |
| 2021-08-18 | OCGN | Mixed | — | -$206.4K | EDGAR |
| 2021-07-16 | OCGN | Mixed | — | -$197.7K | EDGAR |
| 2021-06-17 | OCGN | Mixed | — | -$206.5K | EDGAR |
| 2021-05-14 | OCGN | Mixed | — | -$243.1K | EDGAR |
| 2021-05-03 | OCGN | Mixed | — | -$70.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.